| Project/Area Number |
26670579
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | The University of Tokyo (2015)
Kyoto University (2014) |
|---|
Principal Investigator |
Sato Masaaki 東京大学, 医学部附属病院, 講師 (00623109)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
Menju Toshi 京都大学, 医学(系)研究科(研究院), 助教 (30527081)
Aoyama Akihiro 京都大学, 医学(系)研究科(研究院), 助教 (60379047)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 癌免疫 / 癌ワクチン / 肺癌 / 制御性T細胞 / 粘膜免疫 |
|---|
| Outline of Final Research Achievements |
The purpose of the present study was to establish a "cancer vaccine inhalation therapy" as a novel platform of cancer immunotherapy. Particularly, a novel animal model implanting a B6-mice-derived lung cancer cell line (Liewis cells) into the lung of immunocompetent wild-type B6 mice enabled observation of the hosts' immune response to cancer cells in vivo. Administration of dead cancer cells in combination with adjuvant BCG resulted in attenuation of cancer-relate weight loss and improvement in survival. This effect was further enhanced by combining with systemic administration of low-dose cyclophosphamide, which reduces regulatory T cells in a relatively selective manner. The manuscript describing the outcomes of this study is under submission for a medical journal.
|
